Ionis Pharmaceuticals Inc
IONS
Market Cap$5.49B
Close$
$-20.54
155.1% downside
Current Fair Value
155.1% downsideOvervalued by 155.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $5.49 Billion |
|---|---|
| Enterprise Value | $4.56 Billion |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $-2.67 |
| Beta | 0.51 |
| Outstanding Shares | 145,965,374 |
| Avg 30 Day Volume | 1,082,207 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -14.27 |
|---|---|
| PEG | -96.01 |
| Price to Sales | 7.46 |
| Price to Book Ratio | 18.66 |
| Enterprise Value to Revenue | 5.87 |
| Enterprise Value to EBIT | -11.72 |
| Enterprise Value to Net Income | -12 |
| Total Debt to Enterprise | 0.28 |
| Debt to Equity | 4.3 |
Revenue Sources
No data
ESG Score
No data
About Ionis Pharmaceuticals Inc
817 employees
CEO: Brett Monia Ionis Pharmaceuticals is a biotechnology company based in Carlsbad, California that specializes in discovering and developing RNA-targeted therapeutics. The company has 3 commercially approved medicines: Spinraza , Tegsedi , and WAYLIVRA...